A methods‐based biotechnology course for undergraduates

This new course in biotechnology for upper division undergraduates provides a comprehensive overview of the process of drug discovery that is relevant to biopharmaceutical industry. The laboratory exercises train students in both cell‐free and cell‐based assays. Oral presentations by the students delve into recent progress in drug discovery. Combination of lectures, hands‐on experiments, oral presentations, and accurate recording of laboratory data provides students a thorough training in biotechnology that better prepares them for the job market.

[1]  Thomas Tuschl,et al.  siRNAs: applications in functional genomics and potential as therapeutics , 2004, Nature Reviews Drug Discovery.

[2]  Rick Ng.  Drugs: From Discovery to Approval , 2004 .

[3]  A. Sands,et al.  Predicting drug efficacy: knockouts model pipeline drugs of the pharmaceutical industry. , 2003, Current opinion in pharmacology.

[4]  Solomon Nwaka,et al.  Innovative lead discovery strategies for tropical diseases , 2006, Nature Reviews Drug Discovery.

[5]  Lucia Altucci,et al.  Design of selective nuclear receptor modulators: RAR and RXR as a case study , 2007, Nature Reviews Drug Discovery.

[6]  A. Sands,et al.  Knockouts model the 100 best-selling drugs—will they model the next 100? , 2003, Nature Reviews Drug Discovery.

[7]  Susan R. George,et al.  G-Protein-coupled receptor oligomerization and its potential for drug discovery , 2002, Nature Reviews Drug Discovery.

[8]  John P. Overington,et al.  How many drug targets are there? , 2006, Nature Reviews Drug Discovery.

[9]  William Loging,et al.  High-throughput electronic biology: mining information for drug discovery , 2007, Nature Reviews Drug Discovery.

[10]  Hans Clevers,et al.  Mining the Wnt pathway for cancer therapeutics , 2007, Nature Reviews Drug Discovery.

[11]  Gerhard Hessler,et al.  Drug Design Strategies for Targeting G-Protein-Coupled Receptors , 2002 .

[12]  M. Gibaldi,et al.  Biotechnology and Biopharmaceuticals: Transforming Proteins and Genes into Drugs , 2003 .

[13]  Lee L. Rubin,et al.  Targeting the Hedgehog pathway in cancer , 2006, Nature Reviews Drug Discovery.

[14]  P. Cohen.  Protein kinases — the major drug targets of the twenty-first century? , 2002, Nature reviews. Drug discovery.

[15]  P. Imming,et al.  Drugs, their targets and the nature and number of drug targets , 2006, Nature Reviews Drug Discovery.

[16]  Hans-Joachim Böhm,et al.  A guide to drug discovery: Hit and lead generation: beyond high-throughput screening , 2003, Nature Reviews Drug Discovery.

[17]  Jonathan Knowles,et al.  A guide to drug discovery: Target selection in drug discovery , 2003, Nature Reviews Drug Discovery.

[18]  L. Altucci,et al.  RAR and RXR modulation in cancer and metabolic disease , 2007, Nature Reviews Drug Discovery.

[19]  Frank Petersen,et al.  Small-molecule antagonists of the oncogenic Tcf/β-catenin protein complex , 2004 .

[20]  D. Pompliano,et al.  Drugs for bad bugs: confronting the challenges of antibacterial discovery , 2007, Nature Reviews Drug Discovery.

[21]  I. Irminger-Finger,et al.  Cancer therapy: new drugs are emerging based on molecular targeting but still many challenges. , 2007, The international journal of biochemistry & cell biology.

[22]  Frank Petersen,et al.  Small-molecule antagonists of the oncogenic Tcf/beta-catenin protein complex. , 2004, Cancer cell.

[23]  Hans Clevers,et al.  Mining the Wnt pathway for cancer therapeutics , 2006, Nature Reviews Drug Discovery.

[24]  Gerhard Hessler,et al.  Drug Design Strategies for Targeting G‐Protein‐Coupled Receptors , 2002, Chembiochem : a European journal of chemical biology.